Superseded
Draft standard
Historical
DIN 58989:2017-11
Haemostaseology - HPLC-MS methods for the quantification of direct oral anticoagulants (DOAC) - Rivaroxaban; Text in German and English
Preview
Summary
Rivaroxaban (rINN) is an oral, highly selective direct Factor Xa (FXa) Inhibitor and has an anti-coagulatory effect. This draft standard describes methods for measuring concentrations of the direct oral anticoagulant (DOAC) rivaroxaban in human plasma samples. This document is applicable to developers and manufacturers of rivaroxaban assays, medical laboratories, as well as institutions and commercial organizations performing biomedical research.
Technical characteristics
| Publisher | Deutsche Institut für Normung e.V. (DIN) |
| Publication Date | 11/01/2017 |
| Cancellation Date | 10/01/2018 |
| Page Count | 23 |
| EAN | --- |
| ISBN | --- |
| Weight (in grams) | --- |
No products.
Previous versions
